Enanta Pharmaceuticals Inc (ENTA) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Enanta Pharmaceuticals Inc  (NASDAQ: ENTA)


Enanta Pharmaceuticals Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Enanta Pharmaceuticals Inc's ROI in the third quarter of 2026?
Enanta Pharmaceuticals Inc recorded a cumulative net loss of $-63 million during 12 months ending in the third quarter of 2026, resulting in a negative return on investment (ROI) of -25.93%.

Within the Healthcare sector 345 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 3257 to 3415.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
III. Quarter		 (Mar 31 2026)
II. Quarter		 (Dec 31 2025)
I. Quarter		 (Sep 30 2025)
IV. Quarter		 (Jun 30 2025)
III. Quarter
Y / Y Investment Change TTM -16.76 % -21.24 % -25.41 % -23.5 % -21.81 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 243 268 232 232 256
Return On Investment (TTM) -25.93 % -25.07 % -28.68 % -30.19 % -31.41 %
ENTA's Overall Ranking # 3415 # 3257 # 2816 # 3018 # 2861
Seq. Investment Change TTM -1.39 % -0.88 % -8.01 % -7.42 % -6.7 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -63 -62 -72 -82 -92

ENTA Company Profile >> Back to ENTA Roi Comparisons >> See Annual ENTA Return On Investment



Return On Investment ENTA's Ranking
Within: No.
Industry # 130
Sector # 346
Overall # 3415

Return On Investment Statistics
High Average Low
67.76 %
-4.94 %
-37.24 %
(Mar 31 2015)   (Jun 30 2023)







Financial Statements
Enanta Pharmaceuticals Inc's III. Quarter Investments $ 243 Millions ENTA's Balance sheet
Enanta Pharmaceuticals Inc's III. Quarter Income $ -20 Millions Quarterly ENTA's Income Statement
ENTA's Income by Division See ENTA's Income by Division


ENTA Annual Return On Investment (Sep 30 2025)
2025		 (Sep 30 2024)
2024		 (Sep 30 2023)
2023		 (Sep 30 2022)
2022		 (Sep 30 2021)
2021
Total Investments in Millions 232 319 399 346 403
Y / Y Investment Growth -27.24 % -20.12 % 15.6 % -14.17 % -12.85 %
Net Income in Millions -82 -116 -134 -122 -79
Y / Y Net Income Growth - - - - -
Annual Return On Investment -35.27 % -36.36 % -33.5 % -35.23 % -19.62 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ENTA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ENTA's Competitors
Subscribers only: Roi for Enanta Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for ENTA's Customers

Other Ratios
ENTA's Roa ENTA's Inventory Turnover Ratio ENTA's Growth Rates ENTA's Dividend Statistics
ENTA's Profitability Ratios ENTA's Asset Turnover Ratio ENTA's Dividend Growth
ENTA's Roe ENTA's Valuation Ratios ENTA's Financial Strength Ratios ENTA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T06:55:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.